Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy and Androgen Deprivation in Combination After Local Surgery (RADICALS-RT timing randomisation)
2006-000205-34Phase 3Unknown
- Sponsor
- University College London
- Start
- Dec 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin, Leuplin SR 11.25 mg, triptorelin, buserelin and bicalutamide in prostate cancer (PCa) (2 arms), sponsored by University College London. Primary endpoint: Freedom from distant metastases. Status: unknown.
02
Drugs
goserelinLeuplin SR 11.25 mgtriptorelinbuserelinbicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-000205-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000205-34.